ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc.
- Market cap
- $297.56M
Your view on SPRY
Overview
What the company does, where it operates, and who runs it.
About ARS Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard E. Lowenthal MSMSEL
- Headquarters
- 3525 Del Mar Heights Road, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard E. Lowenthal MSMSEL
- Headquarters
- 3525 Del Mar Heights Road, San Diego, CA, US
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray.
The company was incorporated in 2015 and is based in San Diego, California.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for ARS Pharmaceuticals, Inc.. Starting points for ARS Pharmaceuticals, Inc.: EPS -$2.00, beta 0.88 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for ARS Pharmaceuticals, Inc.. Trailing twelve-month EPS for ARS Pharmaceuticals, Inc. stands at -$2.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
3 firms, last 12 months- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.28 | −$0.29 | −$1.81 | −$0.74 |
| Lowest estimate | −$0.34 | −$0.34 | −$1.89 | −$0.87 |
| Highest estimate | −$0.21 | −$0.22 | −$1.74 | −$0.64 |
| Number of analysts | 2 | 2 | 3 | 3 |
| A year ago | −$0.42 | −$0.61 | −$1.74 | — |
| Growth vs a year ago | +32.7% | +53.0% | −4.0% | — |
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $29.52M | $25.19M | $120.44M | $165.44M |
| Lowest estimate | $28.12M | $24.25M | $119.28M | $144.34M |
| Highest estimate | $30.92M | $26.14M | $121.60M | $186.54M |
| Number of analysts | 3 | 2 | 3 | 3 |
| A year ago | $28.09M | $22.68M | $84.28M | — |
| Growth vs a year ago | +5.1% | +11.1% | +42.9% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for ARS Pharmaceuticals, Inc.. ARS Pharmaceuticals, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AQSTAquestive Therapeutics, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $434.9M | ||
| MNKDMannKind Corporation | Healthcare | Biotechnology | $1.2B | ||
| XERSXeris Biopharma Holdings, Inc. | Healthcare | Biotechnology | $3.1B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PZRXQPhaseRx, Inc. | Healthcare | OTC | $1,169 | ||
| QNCXQuince Therapeutics, Inc. | Healthcare | NASDAQ | $8.8M | ||
| QNRXQuoin Pharmaceuticals, Ltd. | Healthcare | NASDAQ | $6.6M | ||
| QNTMQuantum BioPharma Ltd. | Healthcare | NASDAQ | $8.3M | ||
| QPTFFQuest PharmaTech Inc. | Healthcare | OTC | $2.2M | ||
| QTTBQ32 Bio Inc. | Healthcare | NASDAQ | $249.6M | ||
| QUREuniQure N.V. | Healthcare | NASDAQ | $1.4B | ||
| RAC.AXRace Oncology Limited | Healthcare | ASX | — | ||
| RAD.AXRadiopharm Theranostics Limited | Healthcare | ASX | — | ||
| RADXRadiopharm Theranostics Limited | Healthcare | NASDAQ | $812,081 | ||
| RANIRani Therapeutics Holdings, Inc. | Healthcare | NASDAQ | $33.4M | ||
| RAPPRapport Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $1.1B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | $10.0B in assets | 0.08% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.01% | |
| SMLFiShares US Small-Cap Equity Factor ETF | $4.2B in assets | 0.01% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.01% | |
| SPGMState Street SPDR Portfolio MSCI Global Stock Market ETF | $1.7B in assets | 0.01% | |
Largest holders first, then the funds most concentrated in SPRY.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold ARS Pharmaceuticals, Inc., and how their positions are changing. At a $297.6M market value, institutional positions materially move ARS Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by ARS Pharmaceuticals, Inc. executives and directors. Shares of ARS Pharmaceuticals, Inc. have traded between $6.95 and $18.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for ARS Pharmaceuticals, Inc.. Coverage tracks ARS Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of ARS Pharmaceuticals, Inc.